Analytical Data
-
Gene name
BCL2A1
-
简介
The BCL2A1 protein plays a critical role in resisting apoptosis triggered by IL-3 deprivation, suggesting its importance in the response of hematopoietic cells to external signals and may be involved in protecting endothelial cell survival during infection. It also inhibits serum starvation-induced apoptosis in mammary epithelial cells (HC11). BCL2A1 Protein, Human (His) is the recombinant human-derived BCL2A1 protein, expressed by E. coli , with N-His labeled tag.
- Application
-
Alternative Names
Bcl-2-related protein A1; Protein BFL-1; BCL2L5; BFL1; GRS; HBPA1
-
Species
Human
-
Source
E. coli
-
Tag
N-6*His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q16548
-
Expression Region
M1-S152
-
Protein Length
Partial
-
Molecular Weight
16-17 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCL2A1, a member of the Bcl-2 family of proteins, plays a crucial role in regulating apoptosis and cell survival, making it a significant focus of cancer research. This protein is known to inhibit apoptosis by preventing the mitochondrial release of cytochrome c and the activation of caspases, which are essential for the execution of programmed cell death. Abnormal expression of BCL2A1 has been linked to various cancers, including breast, prostate, and others, where it contributes to tumorigenesis by promoting cell survival in the presence of stress signals, such as chemotherapeutic agents. As cancer therapies aim to induce apoptosis in malignant cells, understanding the functional mechanisms of BCL2A1 becomes vital. Research into BCL2A1 often involves the production of recombinant proteins to study their structural and functional properties, as well as their interactions with other apoptotic regulators. These studies help clarify the role of BCL2A1 in the apoptotic pathway and its potential as a therapeutic target. Inhibiting BCL2A1 could enhance the efficacy of existing cancer therapies, thereby improving treatment outcomes. Consequently, the development of BCL2A1-targeted strategies is an area of active investigation in cancer biology, emphasizing the need for comprehensive studies involving its recombinant expression, characterization, and modulation in different cellular contexts.
